Dante Genomics and TMA Precision Health Partner Over Clinical Whole Genome Sequencing

Dante Genomics and TMA Precision Health are partnering over clinical whole genome sequencing for patients with rare diseases.

The terms of the deal have Dante Genomics providing 30X whole genome sequencing, clinical interpretation, and personalized genomic reports to TMA’s patient network to assist with diagnoses.

Dante Genomics said it will use the genomic data to advance internal research related to novel target identification and drug development, with the ultimate goal of treating rare diseases.

TMA will incorporate the data from this partnership to continue growing its rare disease database, with a focus on developing precision medicine solutions for the 3.5 million patients impacted, said Dante.

The financial terms of the partnership were not disclosed.